Ronald Reagan Building and International Trade Center
Washington, D.C.
In 2022, a historic surgery implanted a genetically modified pig heart into a patient with terminal heart disease. The success of this surgery is predicted to result in a global increase in the xenotransplantation market to remedy the insufficient supply of transplantable human organs. This session will explore this breakthrough technology, opine on future FDA regulation of this field and consider the opportunities for FDA-regulated industry.
Hillary Crowder
hcrowder@wsgr.comGeorgia Ravitz is a partner in the life sciences practice of Wilson Sonsini Goodrich & Rosati, where she specializes in FDA regulatory, healthcare, and consumer products innovation and compliance. In particular, she focuses on food and drug law and regulatory policy governing the regulation and promotion of medical devices, pharmaceuticals (including OTCs), health and beauty aids (cosmetics), dietary supplements, vitamins, food and agribusiness, tobacco and e-cigarettes, cannabis, and a wide variety of consumer goods and emerging consumer technologies. She counsels U.S. and foreign manufacturers, distributors, retailers, and importers of regulated products in all phases of their product lifecycle, from innovation through product commercialization and ongoing post-market compliance.